Advancing a chemistry-driven approach to targeting the microbiome to treat disease & improve human health. Community Guidelines: https://xitter.gq/t.co/Ef4RAU7eMT
Susan Stewart, SVP, Regulatory Affairs & Quality @KaleidoBio talks to The Medicine Maker about the company's lead candidate, KB195, and the regulatory atmosphere that companies pursuing microbiome-based therapeutics face.
ed.gr/bxc9d
Katharine Knobil, CMO and head of R&D @KaleidoBio introduces a novel chemistry driven approach to the development of #microbiome based therapeutics 💊 – at Boston, MA